Dec 5 Reuters GSK said on Thursday it had expanded its agreement with China39;s largest vaccine company Zhifei to explore a potential collaboration on the British drugmaker39;s respiratory syncytial virus RSV vaccine, Arexvy.

Last year, Londonlisted GSK said Zhifei would pay it 2.5 billion pounds 3.18 billion for the exclusive rights to distribute GSK39;s shingles vaccine, Shingrix, in the world39;s No.2 pharmaceuticals market.

GSK said on Thursday it has revised the terms on which Zhifei will commercialise Shingrix in China to 2034.

Under the revised agreement, Zhifei has also agreed to engage exclusively with GSK to explore a potential collaboration on Arexvy, with an initial term of 10 years.

The companies expect that Zhifei will purchase volumes of Shingrix, phased over time, with a potential total value to GSK of 2.3 billion pounds 2.93 billion over the sixyear period from 2024 to 2029.

1 0.7860 pounds

Reporting by Yadarisa Shabong in Bengaluru; Editing by Savio D39;Souza and Rashmi Aich

Source Reuters